News

June 22, 2021

Allysta Pharmaceuticals, Inc. Announces Initiation of Dosing in OASIS-1 Phase 2b/3 Clinical Trial (ALY688-301 Study) Evaluating the Efficacy and Safety of ALY688 Ophthalmic Solution in Dry Eye

June 10, 2021

Allysta Pharmaceuticals, Inc. Announces Start of Phase 1 Clinical Trial of ALY688-SR, a Novel First-in-Class Peptide that Targets Adiponectin Signaling

 

December 15, 2020

Allysta Pharmaceuticals, Inc. Announces Positive Preclinical Data in a NASH Model Demonstrating its Adiponectin Analogue ALY688 Reduces Liver Fat, Inflammation, and Fibrosis

   

December 1, 2020

Allysta Pharmaceuticals, Inc. Announces Positive Results from its Phase 1/2a Clinical Trial of ALY688 Ophthalmic Solution in Dry Eye Disease

   

January 8, 2020

Allysta Pharmaceuticals, Inc. Doses First Patient with ALY688 Ophthalmic Solution in Phase 1/2a Dry Eye Study

   

December 18, 2019

Allysta Pharmaceuticals, Inc. Raises Additional $5 Million in Series A Financing to Advance Novel Therapeutic for NASH

April 25, 2019

Allysta Pharmaceuticals, Inc. to Present at OIS@ASCRS

   

April 22, 2019

Allysta Pharmaceuticals, Inc. to Present New Results on ALY688 at the Annual Meeting of ARVO

April 16, 2019

Allysta Pharmaceuticals, Inc. Raises $15 Million in

Series A Financing to Advance Novel Therapeutic for Dry Eye Disease 

   

April 4, 2018

Allysta Pharmaceuticals, Inc. Doses First Patient in Phase 2A Study in Glaucoma

   

May 13, 2017

Data on Allysta Pharmaceuticals’ Lead Compound, ADP355, Presented at the Annual Meeting of ARVO in Baltimore MD

Poster presented by Prof KC Yoon, Chairman, Dept Ophthalmology, Chonnam University, Korea

   

February 22, 2017

Allysta Pharmaceuticals, Inc. to present at the QB3 – 2017 Life Science Pitch Summit

   

February 22, 2017

Allysta Pharmaceuticals, Inc. to present at the National Investment Banking Association Conference

   

December 12, 2016

Allysta Pharmaceuticals, Inc. to present at the Ninth Annual Biotech Showcase Conference in San Francisco